Pharm Country

Found 132,052 articles

• MindMed to Participate at Upcoming Investor Conferences

  6/1/2023

  Mind Medicine announced today that members of the Company’s management team will participate in the following investor conferences.

• PaxMedica Completes HAT-301 Registrational Trial for PAX-101

  6/1/2023

  PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD), and other serious conditions with intractable neurologic symptoms, today announced that the eligibility review and final enrollment for the company’s Real World Evidence study (HAT-301) has been completed.

• BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference

  6/1/2023

  BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Healthcare Conference being held June 7-9, 2023 at the Marriot Marquis in New York.

• LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

  6/1/2023

  LAVATherapeutics N.V. (Nasdaq:LVTX), a company in the clinical stage of immuno-oncology, is dedicated to advancing its unique Gammabody™ platform, which involves the development of bispecific gamma-delta T cell engagers.

• Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023

  5/31/2023

  Intercept Pharmaceuticals, Inc. announced that it will be participating in investor meetings at the Jefferies Healthcare Conference at the Marriott Marquis in New York City on June 7-8, 2023.

• Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day

  5/31/2023

  Biohaven Ltd. will provide an overview of clinical progress, regulatory updates, and pipeline developments at an in-person R&D Day , concurrently with the Yale Ventures' Innovation Summit 2023 taking place on May 31-June 1.

• Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

  5/31/2023

  Aquestive Therapeutics, Inc. released topline clinical data from recent pilot studies that were completed following the End-of-Phase 2 meeting with the FDA.

• Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress

  5/31/2023

  Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced an upcoming oral presentation by Ryo Otsuka, Ph.D., and poster presentation by Kohei Kinoshita, M.D at the 2023 American Transplant Congress.

• Cabaletta Bio to Present at the 2023 Jefferies Healthcare Conference

  5/31/2023

  Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer, will present a company presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 10:30 a.m. ET in New York, NY.

• Analog Pharma and Dipharma announce US FDA approval of abbreviated new drug application (ANDA) of 20 mg generic Nitisinone capsules (temperature stable)

  5/31/2023

  Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration.

• HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

  5/31/2023

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’) today announced positive preliminary data from its ongoing Phase 2 study of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and neck cancer.

• Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

  5/31/2023

  Cellectis today publishes an article in Cancer Immunology Research demonstrating pre-clinical proof-of-concept data of UCART20x22 product candidate, Cellectis’ first allogeneic dual CAR T-cell targeting the CD20 and CD22 antigens.

• Verrica Pharmaceuticals Announces Presentation at the 2023 Jefferies Healthcare Conference in New York

  5/31/2023

  Verrica Pharmaceuticals Inc. announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Healthcare Conference, which is being held at the New York Marriot Marquis from June 7-9, 2023.

• Arbutus to Present at Jefferies 2023 Healthcare Conference

  5/31/2023

  Arbutus Biopharma Corporation announced that the Company will participate in a fireside chat at the Jefferies Healthcare Conference taking place in New York on Wednesday, June 7, 2023 at 9:30 am ET.

• Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies

  5/31/2023

  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-585. CDX-585 combines highly active PD-1 blockade with anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells.

• Laxxon Medical Announces Formation of Scientific Advisory Board with Renowned Pharmaceutical Experts to Support Pipeline and Life Cycle Management

  5/31/2023

  Laxxon Medical announced today the establishment of its Scientific Advisory Board (SAB), which is comprised of a diverse group of internationally renowned and experienced leaders and experts in the fields of pharmaceutical and chemical thought, application, development, material science and regulatory research.

• DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting

  5/31/2023

  DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

• Enterin announces FDA acceptance of an investigator sponsored IND to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01

  5/31/2023

  Enterin Inc. announces the acceptance by the U.S. Food and Drug Administration (FDA) of an investigator sponsored Investigational New Drug (IND) application (166532) to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01.

• Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

  5/31/2023

  Rocket Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RP-A501, the Company’s investigational adeno-associated virus (AAV)-based gene therapy for the treatment of Danon Disease.

• NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

  5/31/2023

  NanoViricides, Inc., announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET.